Table 4 Comparative analysis of the therapeutic effect of UCMSCs in group A vs group C and group B vs group D at different time points
Outcome | Group | W0–W1 | W1–W4 | W4–W12 | W12–W24 | ||||
|---|---|---|---|---|---|---|---|---|---|
Value | P value | Value | P value | Value | P value | Value | P value | ||
ALT | Group A | 37.5 (5.25–214) | NS | 5 (− 6 to 42) | NS | 8 (− 1.25 to 23.5) | NS | − 3 (− 11 to 5) | NS |
Group C | 19 (2–48) | − 0.5 (− 9.3 to 10.25) | 2.5 (− 0.5 to 11) | − 4 (− 12 to 60) | |||||
Group B | 24 (9–260) | 0.042 | 22.5 (6.2–45.3) | NS | − 6 (− 15 to 6) | NS | 0.5 (− 4 to 5.5) | NS | |
Group D | 12.5 (− 0.5 to 98.5) | 9.5 (− 0.75 to 9.5) | − 6 (− 24.5 to 3.5) | 5.5 (0.25–7) | |||||
AST | Group A | 17 (− 5.5 to 60.25) | NS | − 1 (− 17 to 11) | NS | 26 (6–53.5) | NS | 9 (− 5 to 20) | NS |
Group C | 13 (4–28) | − 7.5 (− 16.75 to 17) | 26 (7.5–40.25) | − 3 (− 15 to 9) | |||||
Group B | 24 (− 10 to 52) | NS | 16 (− 1 to 43.75) | NS | 1 (− 15 to 22) | NS | 3 (− 0.25 to 14.5) | NS | |
Group D | 4 (− 4 to 33.75) | 7.5 (− 7 to 21.25) | 4 (− 11.5 to 9) | 8.5 (3.25–17) | |||||
PTA | Group A | 4 (− 1.75 to 6) | NS | − 1 (− 7 to 3.5) | NS | − 7 (− 15.5 to 0.5) | NS | − 3 (− 5.7 to 2.1) | NS |
Group C | 5 (− 4 to 7) | − 1 (− 7 to 2.5) | − 7 (− 11.75 to 1.5) | − 2 (− 4.1 to 1.9) | |||||
Group B | − 2 (− 4 to 3) | NS | − 5 (− 12 to − 1) | NS | − 15 (− 22.5 to − 4.75) | NS | − 4 (− 7.2 to 1.9) | NS | |
Group D | − 2 (− 8 to 1) | − 10 (− 19 to − 4) | − 4 (− 14.5 to 5) | − 3 (− 5.2 to 2.6) | |||||
MELD | Group A | − 1 (− 2 to 1) | NS | 1 (− 1 to 2.5) | NS | 6.11 ± 5.32 | NS | 2.14 ± 1.71 | NS |
Group C | 0 (− 1 to 2) | 1 (− 1 to 3) | 4 (0.5–7) | 2.4 (0.1–5.3) | |||||
Group B | 1 (− 1 to 2) | NS | 4 (2–6) | NS | 6.86 ± 5.01 | NS | 1.96 ± 1.64 | NS | |
Group D | 2 (0–4) | 4 (1–6.5) | 0.5 (− 0.75 to 5.5) | 3.3 (− 0.5 to 4.9) | |||||